Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.60 |
| ▸ | SYK | P43405 | 2/20 | 0.57 |
| ▸ | TLR4 | O00206 | 1/20 | 0.52 |
| ▸ | TLR2 | O60603 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8877675 | 0.84 | SYK (0.58) | MAOBSYKTLR4TLR2CYP3A4 | |
| SCHEMBL22964159 | 0.81 | TLR4 (0.53) | SYKTLR4TLR2CYP3A4APP | |
| SCHEMBL30361386 | 0.81 | PARP10 (0.64) | MAOBSYKCYP3A4PARP10ALDH1A1 | |
| SCHEMBL3571325 | 0.81 | PARP10 (0.64) | MAOBSYKCYP3A4PARP10ALDH1A1 | |
| SCHEMBL791890 | 0.80 | FFAR1 (0.61) | MAOBSYKTLR4TLR2APP | |
| SCHEMBL22597086 | 0.80 | TLR4 (0.52) | SYKTLR4TLR2CYP3A4PARP10 | |
| SCHEMBL29468767 | 0.80 | MAOB (0.60) | MAOBTLR4TLR2PARP10ALDH1A1 | |
| SCHEMBL13645800 | 0.80 | KDM4E (0.55) | SYKTLR4TLR2TP53ALDH1A1 | |
| SCHEMBL2649525 | 0.80 | MAOB (0.60) | MAOBTLR4TLR2PARP10ALDH1A1 | |
| SCHEMBL6445371 | 0.80 | KCNH2 (0.67) | MAOBSYKTLR4TLR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104496982-A | Kinase Inhibitors, Prodrug Forms Thereof And Their Use In Therapy | AUCKLAND UNISERVICES LTD | 2015-04-08 | — | — | CN | claimed |
| US-9573887-B2 | Naphthalene derivative | DAITO CHEMIX CORPORATION (JP) | 2017-02-21 | — | — | US | disclosed |
| EP-2599771-B1 | NAPHTHALENE DERIVATIVE | DAITO CHEMIX CORP (JP) | 2016-09-14 | — | — | EP | disclosed |
| CN-104496982-A | Kinase Inhibitors, Prodrug Forms Thereof And Their Use In Therapy | AUCKLAND UNISERVICES LTD | 2015-04-08 | — | — | CN | disclosed |
| US-20130184241-A1 | Naphthalene Derivative | KYOTO UNIVERSITY (JP) | 2013-07-18 | — | — | US | disclosed |
| EP-2599771-A1 | NAPHTHALENE DERIVATIVE | Daito Chemix Corporation (JP) | 2013-06-05 | — | — | EP | disclosed |
| CN-1092409-A | The compound that is used for the treatment of leukotriene-related disease | SMITHKLINE BEECHAM CORP (US) | 1994-09-21 | — | — | CN | disclosed |
| CN-1073431-A | The compound that is used for the treatment of leukotriene-related disease | SMITHRLINE BEECHAM CORP (US) | 1993-06-23 | — | — | CN | disclosed |
| US-5157039-A | Lipoxygenase inhibitors | LEO PHARMACEUTICAL PRODUCTS LTD. (DK) | 1992-10-20 | — | — | US | disclosed |
| US-5109009-A | QUINOLINE AND PYRIDINE COMPOUNDS AND INHIBITION OF 5-LIPOXYGENASES THEREWITH | LEO PHARMACEUTICAL PRODUCTS LTD. (DK) | 1992-04-28 | — | — | US | disclosed |
| CN-1058015-A | Benzoic acid derivative | SMITHKLINE BEECHAM CORP (US) | 1992-01-22 | — | — | CN | disclosed |
| US-4826987-A | Pyridyl and quinoline derivatives | LEO PHARMACEUTICAL PRODUCTS LTD. (DK) | 1989-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184241-A1 | Naphthalene Derivative | VCP, NOC2L, VAT1 | MAOB 2080/4885SYK 4877/4885TLR4 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.